Emerging pharmacotherapeutic strategies for cholangiocarcinoma

Constantin A. Dasanu, Shounak Majumder, Guru Trikudanathan

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Although of limited clinical benefit, chemotherapy represents the cornerstone of management for patients with inoperable cholangiocarcinoma. The literature on chemotherapy in advanced cholangiocarcinoma is difficult to interpret because of the heterogeneity of cholangiocarcinoma, the use of various chemotherapeutic agents in different combinations and dosing regimens, and the small size of existing patient cohorts. Areas covered: The authors discuss the major advances in the therapy of cholangiocarcinoma over the past decade. The audience will become familiarized with the contemporary medical management of cholangiocarcinoma and potentially useful agents/combinations for the therapy of this entity in the future. Expert opinion: In recent years, gemcitabine-based chemotherapy has improved overall survival in advanced cholangiocarcinoma. Although gemcitabinecisplatin combination represents the largely accepted standard for biliary cancers at present, very few studies so far have looked at the results in cholangiocarcinoma patients only. Therefore, large multicenter, randomized clinical trials are essential to identify the optimal treatment strategy for this rare tumor. In addition, regimens employing gemcitabine with oxaliplatin and/or fluoropyrimidines have shown promising results and warrant additional investigation in cholangiocarcinoma. The efficacy of a variety of newer agents is also now being tested in clinical trials.

Original languageEnglish (US)
Pages (from-to)1865-1874
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number12
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Cholangiocarcinoma
gemcitabine
oxaliplatin
Drug Therapy
Biliary Tract Neoplasms
Expert Testimony
Therapeutics
Randomized Controlled Trials
Clinical Trials
Survival

Keywords

  • Chemotherapy
  • Cholangiocarcinoma
  • Cisplatin
  • Fluoropyrimidines
  • Gemcitabine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Emerging pharmacotherapeutic strategies for cholangiocarcinoma. / Dasanu, Constantin A.; Majumder, Shounak; Trikudanathan, Guru.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 12, 01.08.2011, p. 1865-1874.

Research output: Contribution to journalReview article

Dasanu, Constantin A. ; Majumder, Shounak ; Trikudanathan, Guru. / Emerging pharmacotherapeutic strategies for cholangiocarcinoma. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 12. pp. 1865-1874.
@article{b4dacf3007cb4fa2a1ea7ba870d3f93f,
title = "Emerging pharmacotherapeutic strategies for cholangiocarcinoma",
abstract = "Introduction: Although of limited clinical benefit, chemotherapy represents the cornerstone of management for patients with inoperable cholangiocarcinoma. The literature on chemotherapy in advanced cholangiocarcinoma is difficult to interpret because of the heterogeneity of cholangiocarcinoma, the use of various chemotherapeutic agents in different combinations and dosing regimens, and the small size of existing patient cohorts. Areas covered: The authors discuss the major advances in the therapy of cholangiocarcinoma over the past decade. The audience will become familiarized with the contemporary medical management of cholangiocarcinoma and potentially useful agents/combinations for the therapy of this entity in the future. Expert opinion: In recent years, gemcitabine-based chemotherapy has improved overall survival in advanced cholangiocarcinoma. Although gemcitabinecisplatin combination represents the largely accepted standard for biliary cancers at present, very few studies so far have looked at the results in cholangiocarcinoma patients only. Therefore, large multicenter, randomized clinical trials are essential to identify the optimal treatment strategy for this rare tumor. In addition, regimens employing gemcitabine with oxaliplatin and/or fluoropyrimidines have shown promising results and warrant additional investigation in cholangiocarcinoma. The efficacy of a variety of newer agents is also now being tested in clinical trials.",
keywords = "Chemotherapy, Cholangiocarcinoma, Cisplatin, Fluoropyrimidines, Gemcitabine",
author = "Dasanu, {Constantin A.} and Shounak Majumder and Guru Trikudanathan",
year = "2011",
month = "8",
day = "1",
doi = "10.1517/14656566.2011.583919",
language = "English (US)",
volume = "12",
pages = "1865--1874",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Emerging pharmacotherapeutic strategies for cholangiocarcinoma

AU - Dasanu, Constantin A.

AU - Majumder, Shounak

AU - Trikudanathan, Guru

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Introduction: Although of limited clinical benefit, chemotherapy represents the cornerstone of management for patients with inoperable cholangiocarcinoma. The literature on chemotherapy in advanced cholangiocarcinoma is difficult to interpret because of the heterogeneity of cholangiocarcinoma, the use of various chemotherapeutic agents in different combinations and dosing regimens, and the small size of existing patient cohorts. Areas covered: The authors discuss the major advances in the therapy of cholangiocarcinoma over the past decade. The audience will become familiarized with the contemporary medical management of cholangiocarcinoma and potentially useful agents/combinations for the therapy of this entity in the future. Expert opinion: In recent years, gemcitabine-based chemotherapy has improved overall survival in advanced cholangiocarcinoma. Although gemcitabinecisplatin combination represents the largely accepted standard for biliary cancers at present, very few studies so far have looked at the results in cholangiocarcinoma patients only. Therefore, large multicenter, randomized clinical trials are essential to identify the optimal treatment strategy for this rare tumor. In addition, regimens employing gemcitabine with oxaliplatin and/or fluoropyrimidines have shown promising results and warrant additional investigation in cholangiocarcinoma. The efficacy of a variety of newer agents is also now being tested in clinical trials.

AB - Introduction: Although of limited clinical benefit, chemotherapy represents the cornerstone of management for patients with inoperable cholangiocarcinoma. The literature on chemotherapy in advanced cholangiocarcinoma is difficult to interpret because of the heterogeneity of cholangiocarcinoma, the use of various chemotherapeutic agents in different combinations and dosing regimens, and the small size of existing patient cohorts. Areas covered: The authors discuss the major advances in the therapy of cholangiocarcinoma over the past decade. The audience will become familiarized with the contemporary medical management of cholangiocarcinoma and potentially useful agents/combinations for the therapy of this entity in the future. Expert opinion: In recent years, gemcitabine-based chemotherapy has improved overall survival in advanced cholangiocarcinoma. Although gemcitabinecisplatin combination represents the largely accepted standard for biliary cancers at present, very few studies so far have looked at the results in cholangiocarcinoma patients only. Therefore, large multicenter, randomized clinical trials are essential to identify the optimal treatment strategy for this rare tumor. In addition, regimens employing gemcitabine with oxaliplatin and/or fluoropyrimidines have shown promising results and warrant additional investigation in cholangiocarcinoma. The efficacy of a variety of newer agents is also now being tested in clinical trials.

KW - Chemotherapy

KW - Cholangiocarcinoma

KW - Cisplatin

KW - Fluoropyrimidines

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=79960466593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960466593&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.583919

DO - 10.1517/14656566.2011.583919

M3 - Review article

C2 - 21585239

AN - SCOPUS:79960466593

VL - 12

SP - 1865

EP - 1874

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -